{"entity":{"id":"t-maximum-pharmaceutical","kind":"company","name":"T-MAXIMUM Pharmaceutical","aka":["T-MAXIMUM Pharmaceutical Inc","T-MAXIMUM"],"tldr":"T-MAXIMUM Pharmaceutical develops ready-made CAR-T cell therapies from healthy donors for solid tumours. Its lead, MT027, targets B7-H3 and is given into the fluid around the brain in trials for recurrent glioblastoma and brain metastases.","summary":"T-MAXIMUM Pharmaceutical is a clinical-stage cell therapy company developing allogeneic CAR-T products for locoregionally accessible solid tumours, with research bases listed in Ningbo, Suzhou, Chongqing, Yantai, Hong Kong and the United States. Its lead, MT027, is an off-the-shelf, donor-derived CAR-T therapy targeting B7-H3; the company announced FDA IND clearance in December 2025 to proceed to a phase 2 trial in recurrent glioblastoma. Its registered phase 2 trials give MT027 by intracerebroventricular injection: GLIOMAX in recurrent glioma (NCT07386002) and METAMAX in brain metastases from advanced solid tumours (NCT07897799). Other pipeline programmes are MT029 (EGFR) and MT026 and MT028 (IL-13R alpha 2 and HER2) in solid tumours. Its first registered cancer trial, NCT07386002, was posted on ClinicalTrials.gov in February 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://t-maximum.com/"},{"label":"MT027 FDA IND clearance, December 2025","url":"https://www.prnewswire.com/news-releases/t-maximum-pharmaceuticals-allogeneic-car-t-therapy-mt027-receives-fda-ind-clearance-to-proceed-to-phase-ii-clinical-trial-for-recurrent-glioblastoma-302647537.html"},{"label":"ClinicalTrials.gov: GLIOMAX phase 2 trial of MT027 (NCT07386002)","url":"https://clinicaltrials.gov/study/NCT07386002"},{"label":"ClinicalTrials.gov: METAMAX phase 2 trial of MT027 (NCT07897799)","url":"https://clinicaltrials.gov/study/NCT07897799"}],"tags":[],"related":[],"cancers":["glioblastoma","secondary-brain-tumours"],"sections":["cell-therapy"],"technologies":["car-t","allogeneic-cell-therapy","glioma-car-t"],"targets":["b7h3","egfr","her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Headquarters not stated on the website; Beijing is the dateline of the December 2025 release, and the company lists research bases in Ningbo, Suzhou, Chongqing, Yantai, Hong Kong and the United States.","Founding year and headquarters not stated on the website or the December 2025 release (datelined Beijing); country follows the Chinese research bases.","The website links ASCO 2024 clinical progress, so MT027 was in human studies before its first ClinicalTrials.gov registration; earlier studies were not traced.","No financing amounts or investors are named.","Company website and December 2025 release read on 29 October 2026."],"hq":"Beijing","country":"CN","companyType":"cell-therapy","website":"https://t-maximum.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/t-maximum-pharmaceutical/","neighbours":{"cancer":[{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"glioma-car-t","kind":"technology","name":"CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)","route":"/technologies/glioma-car-t/"}],"target":[{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}]}}